First Citizens Bank & Trust CO Nektar Therapeutics Transaction History

First Citizens Bank & Trust CO

$6.21 Billion
Q1 2024

A detailed history of First Citizens Bank & Trust CO transactions in Nektar Therapeutics stock. As of the latest transaction made, First Citizens Bank & Trust CO holds 11,686 shares of NKTR stock, worth $14,490. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,686

Previous 27,941 58.18%

Holding current value

$14,490

Previous $15,000 33.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	SELL	$0.49 - $0.96 $7,964 - $15,604	-16,255 Reduced 58.18%	11,686 $10,000
Q4 2023 Jan 22, 2024	SELL	$0.42 - $0.57 $9,815 - $13,320	-23,370 Reduced 45.55%	27,941 $15,000
Q3 2023 Oct 30, 2023	SELL	$0.51 - $1.05 $23,877 - $49,158	-46,818 Reduced 47.71%	51,311 $30,000
Q2 2023 Aug 15, 2023	BUY	$0.53 - $1.03 $52,008 - $101,072	98,129 New	98,129 $56,000
Q1 2022 Apr 26, 2022	SELL	$4.16 - $13.72 $62,054 - $204,661	-14,917 Closed	0 $0

Q4 2021 Mar 11, 2022	BUY	$10.83 - $18.41 $920 - $1,564	85 Added 0.57%	14,917 $202,000
Q3 2021 Oct 15, 2021	BUY	$13.07 - $18.84 $13,226 - $19,066	1,012 Added 7.32%	14,832 $266,000
Q2 2021 Jul 14, 2021	SELL	$16.52 - $20.4 $54,235 - $66,973	-3,283 Reduced 19.2%	13,820 $237,000
Q1 2021 Apr 14, 2021	BUY	$16.56 - $25.46 $82,849 - $127,376	5,003 Added 41.35%	17,103 $342,000
Q4 2020 Jan 13, 2021	BUY	$15.77 - $19.03 $190,817 - $230,263	12,100 New	12,100 $206,000
Q2 2018 Jul 11, 2018	SELL	$46.25 - $104.45 $95,321 - $215,271	-2,061 Closed	0 $0
Q1 2018 Apr 11, 2018	BUY	$57.4 - $108.44 $118,301 - $223,494	2,061 New	2,061 $219,000

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Citizens Bank & Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on First Citizens Bank & Trust CO with notifications on news.

Account

First Citizens Bank & Trust CO Nektar Therapeutics Transaction History